Skip to content

Traumatic Brain Injury Feasibility Study (EPIC-011)

Traumatic Brain Injury (TBI) Feasibility Study to Determine Possible Prognostic Indicators as Provided by the EPIC ClearView™

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02471625
Acronym
TBI
Enrollment
200
Registered
2015-06-15
Start date
2015-04-30
Completion date
Unknown
Last updated
2015-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Controls, Traumatic Brain Injury

Keywords

Controls

Brief summary

The purpose of this research study is to evaluate whether data made by the ClearView System can be used to detect whether someone has a traumatic brain injury and how severe the injury is.

Detailed description

Traumatic brain injury (TBI) is a significant cause of death and disability in the U.S. The severity of a TBI may range from mild (i.e. a brief change in mental status or consciousness) to severe (i.e. an extended period of unconsciousness or memory loss after the injury). However, most TBI's that occur each year are mild and are commonly called concussions. Unfortunately, TBI terminology does not adequately describe the injury or impairment, its treatment, or the resulting outcomes. Due to the complexity of the human brain, each person's physiology can result in different patterns of impairment and secondary conditions, requiring different treatment or rehabilitation. The intent of EPIC ClearView™ TBI Feasibility (EPIC-011) is to collect data to further develop the ClearView™ Response Scale to measure electrophysiology associated with TBI

Interventions

DEVICEClearView Scanning

Sponsors

Epic Research & Diagnostics, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Suspected TBI population: 1. Acute head trauma within 24-72 hours of presentation 2. 18-65 age inclusive 3. GCS of 3-15 on initial evaluation in ED Control population: 1. 18-65 age inclusive 2. GCS score of 15

Exclusion criteria

1. Current neurological disease 2. Current severe psychological disorder 3. History of substance or alcohol abuse 4. Under drug or alcohol influence, if so, must wait at least 24 hrs. prior to consent 5. Documented current diagnosis/treatment of cancer (including Sickle Cell Disease) 6. Current treatment to the head/brain (radiation, whole brain therapy, gamma knife) 7. Head injury in the last two years 8. Unwilling to sign informed consent 9. Pregnant or potentially pregnant 10. Pacemaker, automatic implanted cardiac defibrillator or other implanted electrical device 11. Connected to an electronic device that cannot be removed 12. Missing all or part of fingers or cuts/burns on pads of fingers 13. Long fingernails and unwilling to cut them and keep them cut for the duration of the study 14. Hand tremors or involuntary oscillations (shaking) of the hands that prevents clear imaging Additional

Design outcomes

Primary

MeasureTime frameDescription
Agreement of ClearView Scan versus Active DiagnosisI day unless TBI population chooses to participate in one week follow upThe EPIC ClearView software produces a Response Scale report that summaries the electrophysiological measurements associated with organ systems. The autonomic numbers indicate how the person's stress response is affecting different body systems and the physical numbers reflect physiological function. These measurements will then be compared to TBI diagnosis, based on one or two possible scans

Secondary

MeasureTime frameDescription
Comparison of TBI subjects to Controls1 day unless TBI population chooses to participate in one week follow upWill measure comparisons of data from one visit

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026